At present we do not know whether the therapeutic effect of the C11 double inhibitor is more efficient at recovering brain abnormalities in CDD at different developmental ages than a therapy with a selective GSK-3β or HDAC6 inhibitor. This evidence concerns the gene GSK3B and craniodiaphyseal dysplasia.